Hair Loss with Tepezza

TEPEZZA (teprotumumab-trbw) Causes Hair Loss

TEPEZZA (teprotumumab-trbw) is an insulin-like growth factor-1 receptor inhibitor indicated for the treatment of thyroid eye disease. Clinical studies have shown that about 13 % of patients using this drug have hair loss compared to 8% of controls.

I was interested to read a report by Wang et al of side effects of TEPEZZA (teprotumumab-trbw) found in the FDA Adverse Events Reporting System database. Alopecia was ranked the sixth most common side effect and had a reporting odds ratio of 7.84 (with a confidence interval of 6.75–9.1).

This study reminds us of the hair loss associated with TEPEZZA (teprotumumab-trbw). Patients receiving this drug for thyroid eye disease must be aware of this side effect.

REFERENCE

Wang X-L et al. An observational study on the safety of teprotumumab based on FAERS database. Endocrine. 2024 May 17. doi: 10.1007/s12020-024-03852-x. Online ahead of print.